Enamine Ltd and Exquiron Biotech AG have announced a multiyear collaboration under which Enamine will provide a carefully selected, novel diverse screening compound library.
This library will be made available by Exquiron to screening clients for hit discovery projects.
The library provided by Enamine is a great asset for discovery programs as it includes a high number of diverse drug-like compounds.
Exquiron and its clients will also have access to Enamine’s full range of chemistry expertise, for post screening follow-up.
Dr. Serge Parel, VP Chemistry and Research Informatics, Exquiron, commented: “Offering high quality chemistry to our clients is crucial. We are impressed by the quality and novelty of Enamine’s compounds, coupled with their logistics and support services. Together we can offer clients excellent value.”
“We are pleased that Exquiron has chosen to work with us. We see this as confirmation of the quality of our chemistry and services, and hope that our collaboration will contribute to Exquiron’s success,” added Michael Bossert, Head of Strategic Alliances, Enamine.